Disparities in liver transplantation for metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma

Figure 1 Flowchart of the study population. HCC: Hepatocellular carcinoma; MASH: Metabolic dysfunction-associated steatohepatitis; NH: Non-Hispanic; STAR: Standard Transplant Analysis and Research.

Figure 2 Reason for liver transplantation waitlist removal by race/ethnicity of patients with non-alcoholic steatohepatitis-associated hepatocellular carcinoma.

Figure 3 Proportion of transplanted patients by pre-median/post-median model for end-stage liver disease era at transplant era and race/ethnicity. MMAT: Median model for end-stage liver disease era at transplant.

Figure 4 Proportion of waitlisted patients of all races and ethnicities undergoing transplantation, by United Network for Organ Sharing region.

Figure 5 Outcomes stratified by United Network for Organ Sharing region. A: Proportion of patients with non-alcoholic steatohepatitis-associated hepatocellular carcinoma undergoing liver transplantation, by region and race/ethnicity; B: Proportion of patients dying on the liver transplant waitlist for non-alcoholic steatohepatitis-associated hepatocellular carcinoma, by region and race/ethnicity.